Boston, January 25, 2017 – Cytonome/ST, LLC announces it has signed the first application specific agreement to license its proprietary GigaSortTM Technology for commercial scale cell therapy production. A premier pharmaceutical company has signed on for rights to use the technology for their explicit disease indication. They will manufacture a critical cell therapy to address one of the major diseases afflicting aging populations globally.
The GigaSort Platform is an application specific laser-based cell sorter that allows the identification, characterization, and isolation of highly purified cell populations.
Due to its low pressure parallel microfluidic channel design, the GigaSort Platform provides high throughput processing while remaining gentle on cells. A fully enclosed, single use, fluidic set that contains a microfluidic chip solves the safety and contamination problems that have plagued therapeutic cell sorting applications using conventional aerosol-based cell sorting technologies.
‘We are thrilled to be working with our new partner to use the GigaSort Technology to enable break-through advances in cell therapy by transitioning from proof of concept into accessible, manufacturableproducts.” said John Sharpe, Ph.D., Cytonome’s Chief Technology Officer.
About Cytonome-ST, LLC
Headquartered in Boston, MA, Cytonome/ST, LLC is a privately held biotechnology instrument company with an extensive intellectual property portfolio. Cytonome develops advanced solutions in cell purification for the industrial, clinical and life science research markets. With deep engineering expertise in the cytometry field and a strong intellectual property portfolio, Cytonome aims to develop products that simplify existing workflows and enable leading edge research and therapies. The GigaSort platform is RUO/IUO in the United States. For more information please visit www.cytonome.com.